Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort

Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L792 mutations, a non-covalent mechanism of osimertinib resistance, using Guardant360 cfDNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Fairclough, Stephen R., Kiedrowski, Lesli A., Lin, Jessica J., Zelichov, Ori, Tarcic, Gabi, Stinchcombe, Thomas E., Odegaard, Justin I., Lanman, Richard B., Shaw, Alice T., Nagy, Rebecca J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788107/
https://www.ncbi.nlm.nih.gov/pubmed/31632838
http://dx.doi.org/10.1186/s40164-019-0148-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6788107/
https://www.ncbi.nlm.nih.gov/pubmed/31632838
http://dx.doi.org/10.1186/s40164-019-0148-7

Ejemplares similares